Literature DB >> 12937013

Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Fu-Yu Chiang1, Michael Climo.   

Abstract

The levels of effectiveness of linezolid, vancomycin, and the combination of linezolid and vancomycin were compared in the rabbit model of endocarditis caused by a clinical methicillin-resistant Staphylococcus aureus (MRSA) isolate. Vancomycin alone was more effective than either linezolid alone or the combination of linezolid and vancomycin for the treatment of endocarditis due to MRSA.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12937013      PMCID： PMC182596          DOI： 10.1128/AAC.47.9.3002-3004.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Efficacy of linezolid in a staphylococcal endocarditis rabbit model.

Authors:  M P Oramas-Shirey; L V Buchanan; C L Dileto-Fang; C F Dailey; C W Ford; D H Batts; J K Gibson
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

3.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

4.  Linezolid therapy of Staphylococcus aureus experimental osteomyelitis.

Authors:  R Patel; K E Piper; M S Rouse; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Authors:  E Rubinstein; S Cammarata; T Oliphant; R Wunderink
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

7.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.

Authors:  A S Bayer; K Lam
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  21 in total

1.  Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.

Authors:  Wolfgang A Krueger; Bernd Kottler; Bernd E Will; Alexandra Heininger; Heinz Guggenberger; Klaus E Unertl
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics.

Authors:  Paige M Fox; Russell J Lampen; Katrina S Stumpf; Gordon L Archer; Michael W Climo
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

5.  Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.

Authors:  George Athanassopoulos; Angelos Pefanis; Vissaria Sakka; Dimitrios Iliopoulos; Despina Perrea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

7.  In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Olivier Grossi; Virginie Le Mabecque; Anne-Françoise Miegeville; Denis Bugnon; Eric Batard; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

8.  Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.

Authors:  P Tattevin; A Saleh-Mghir; B Davido; I Ghout; L Massias; C Garcia de la Maria; J M Miró; C Perronne; F Laurent; A C Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 9.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 10.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.